• Antihypertensive and reduced risk for epilepsy, first responders to 9-11 and early dementia risk, FDA approval of donanemab

  • Jul 18 2024
  • Duración: 5 m
  • Podcast

Antihypertensive and reduced risk for epilepsy, first responders to 9-11 and early dementia risk, FDA approval of donanemab

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • In this week’s podcast, Neurology Today’s editor-in-chief discusses data on an angiotensin receptor for blocker for hypertension associated with reduced risk for epilepsy, a study finding first responders to 9-11 clean-up sites had an increased risk for early dementia, and dementia experts comment on approval of donanemab.
    Más Menos
Enfermedades Físicas Hygiene & Healthy Living
Más Menos

Lo que los oyentes dicen sobre Antihypertensive and reduced risk for epilepsy, first responders to 9-11 and early dementia risk, FDA approval of donanemab

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles